$2.410
-0.059 (-2.43%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
IKT Prediction & Forecast by Similar Chart Analysis
Alphio's IKT stock price prediction model matches the current Inhibikase Therapeutics Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.40 (-0.54%). The 1-week path is $2.35 (-2.36%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Inhibikase Therapeutics Inc Stock?
Inhibikase Therapeutics Inc (IKT) is a good buy right now due to its recent earnings performance, where it reported a GAAP EPS of -$0.10, beating expectations of -$0.11, indicating improvements in operational efficiency. Additionally, the company has a strong cash position of $170.4 million, which supports ongoing R&D efforts. However, the main risk is its negative earnings trend, with a forward P/E of 0 and a projected loss of -$16.38 million in Q1 2026.
IKT stock price ended at $2.41 on Friday, after losing -2.43%
Inhibikase Therapeutics Inc (IKT) last closed at $2.41, losing -2.43%. These facts feed the 1-day and 1-week IKT price prediction above.
Forecast Drivers
Inhibikase Therapeutics Inc (IKT) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bearish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches IKT, ranked by similarity.
Seasonality analysis for IKT
Historically the probability of a positive August return for IKT is 49.21%. July offers the highest probability of a positive month at 57.58%, while September is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
10-year price projections for IKT
| Month | Min Price | Avg Price | Max Price | Potential ROI |
|---|---|---|---|---|
| Aug 2026 | $1.63 | $1.85 | $1.89 | -23.16% |
| Sep 2026 | $1.67 | $1.99 | $2.18 | -17.50% |
| Oct 2026 | $1.54 | $1.81 | $1.95 | -24.69% |
| Nov 2026 | $1.50 | $1.64 | $1.87 | -31.86% |
| Dec 2026 | $2.07 | $2.22 | $2.41 | -7.81% |
In 2026, Inhibikase Therapeutics Inc (IKT) is projected to range from $1.50 to $2.41.
Inhibikase Therapeutics Inc 2026 monthly forecast
In Aug 2026, Inhibikase Therapeutics Inc is projected to average $1.85, with a low of $1.63 and high of $1.89.
In Sep 2026, Inhibikase Therapeutics Inc is projected to average $1.99, with a low of $1.67 and high of $2.18.
In Oct 2026, Inhibikase Therapeutics Inc is projected to average $1.81, with a low of $1.54 and high of $1.95.
In Nov 2026, Inhibikase Therapeutics Inc is projected to average $1.64, with a low of $1.50 and high of $1.87.
In Dec 2026, Inhibikase Therapeutics Inc is projected to average $2.22, with a low of $2.07 and high of $2.41.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.